4CMenB vaccine induces elite cross-protective human antibodies that compete with human factor H for binding to meningococcal fHbp

Neisseria meningitidis serogroup B (MenB) is the leading cause of meningococcal meningitis and sepsis in industrialized countries, with the highest incidence in infants and adolescents. Two recombinant protein vaccines that protect against MenB are now available (i.e. 4CMenB and MenB-fHbp). Both vac...

Descripción completa

Detalles Bibliográficos
Autores principales: Veggi, Daniele, Bianchi, Federica, Santini, Laura, Lo Surdo, Paola, Chesterman, Chelsy C., Pansegrau, Werner, Bechi, Nicoletta, Huang, Ying, Masignani, Vega, Pizza, Mariagrazia, Rappuoli, Rino, Bottomley, Matthew J., Cozzi, Roberta, Maione, Domenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556464/
https://www.ncbi.nlm.nih.gov/pubmed/33007046
http://dx.doi.org/10.1371/journal.ppat.1008882

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556464/
https://www.ncbi.nlm.nih.gov/pubmed/33007046
http://dx.doi.org/10.1371/journal.ppat.1008882

Ejemplares similares